HNSCC

Showing 1 posts of 1 posts found.

Immutep achieves FDA Fast Track designation for soluble LAG-3 protein

April 12, 2021
Sales and Marketing FDA, HNSCC

Immutep, a biotechnology company developing novel immunotherapy treatments for cancer, infectious disease, and autoimmune disease, has achieved FDA Fast Track …

Latest content